Dr. James Young Appointed Principal Investigator for Vasogen's Confirmatory Study in NYHA Class II Heart Failure

    MISSISSAUGA, ON, Sept. 19 /CNW/ - Vasogen Inc. (NASDAQ:  VSGN; TSX:VAS),
today announced that James B. Young, MD, Chairman, Division of Medicine at the
Cleveland Clinic Foundation and Medical Director, Kaufman Center for Heart
Failure, has agreed to be the Global Principal Investigator and Chairman of
the Steering Committee for its planned confirmatory study of Celacade(TM) in
patients with NYHA Class II chronic heart failure. Dr. Young, who has played a
leading role in numerous multi-center clinical trials focusing on heart
failure and transplantation, led Vasogen's 2,400-patient ACCLAIM study which
was completed last year and demonstrated a 39% reduction (p equals 0.0003) in
the risk of death or cardiovascular hospitalizations for the large pre-defined
subgroup of 689 patients with NYHA class II heart failure.
    "I am extremely pleased to be participating in this important study for
the purpose of confirming the impressive result seen with the pre-specified
subgroup of nearly 700 patients with NYHA Class II heart failure in the
ACCLAIM study," said Dr. Young. "There is clearly a need for more options to
treat patients with Class II heart failure and Celacade has the potential to
become a safe and effective first-in-class therapy in this progressive and
devastating condition."
    Vasogen recently announced plans for a confirmatory study that would
support an application for regulatory approval in the United States of its
Celacade technology for the treatment of patients with NYHA Class II heart
failure. The planned study involves an adaptive trial design utilizing a
Bayesian statistical approach; as few as 300 patients could provide sufficient
data to confirm the finding in the pre-specified sub-group of ACCLAIM patients
with NYHA Class II heart failure. Furthermore, the use of an adaptive clinical
trial design also provides the flexibility to increase the sample size up to
600 patients, should additional data be required.

    About Dr. James Young

    Dr. Young's clinical research activities began during his residency and
fellowship training when he was a Lipid Research Clinic (LRC) physician. He
subsequently focused his efforts on heart failure and cardiac transplant
therapeutics which included early experiences with dopamine receptor agonists,
angiotensin-converting enzyme inhibitors, beta blockers, calcium channel
blockers, angiotensin receptor blockers, many new immunosuppressants, and a
variety of parenteral inotropes and vasodilators. He has collaborated
extensively with his basic science research associates at the Kaufman Center
for Heart Failure and the Multi-organ Transplant Center on 'bridging' and
'translational' research focused primarily on the molecular biology of cardiac
remodeling, allograft arteriopathy, and transplanted heart rejection.
Dr. Young has also served as the United States Principal Investigator or
Co-Principal Investigator for the HOPE, RESOLVED, SPICE, VMAC, MIRACLE-ICD,
ONTARGET, TRENSCEND, and CHARM multi-center clinical trials. He has published
nearly 500 manuscripts and abstracts and several textbooks. Professionally,
Dr. Young is most proud of his contributions to the development and
administration of organ procurement programs, his efforts to secure
recognition for the newly emerging cardiology subspecialty of "Heart Failure
and Cardiac Transplant Medicine", and his collaborations with basic and
clinical scientists.

    About Heart Failure

    Heart failure, most frequently resulting from coronary artery disease or
hypertension, is a debilitating syndrome in which the heart's ability to
function as a pump is impaired. Patients with heart failure experience a
continuing decline in their health, resulting in an increased frequency of
hospitalization and premature death. According to the Heart Failure Society of
America, heart failure is the only major cardiovascular disease with
prevalence and incidence on the rise. Heart failure, which is now often
referred to as an epidemic, is estimated to affect 12 million individuals in
North America and Europe and an estimated 4.4 million have NYHA Class II
symptomatic impairment.

    About Vasogen

    Vasogen is a biotechnology company engaged in the research and commercial
development of therapies designed to target the destructive inflammatory
process associated with the development and progression of cardiovascular and
neurodegenerative disorders. The Company's lead product, the Celacade(TM)
technology, is designed to activate the immune response to apoptosis - an
important physiological process that regulates inflammation. Celacade(TM) is
in late-stage development for the treatment of chronic heart failure and has
received European regulatory approval under the CE Mark for this indication.
Vasogen is also developing a new class of drugs for the treatment of certain
neuro-inflammatory disorders and is preparing to advance VP025, the lead drug
candidate from this new class, into phase II development.

    Certain statements contained in this press release or elsewhere in our
public documents constitute "forward-looking statements" within the meaning of
the United States Private Securities Litigation Reform Act of 1995 and/or
"forward-looking information" under the Securities Act (Ontario). These
statements may include, without limitation, summary statements relating to
results of the ACCLAIM trial in patients with chronic heart failure, plans to
advance the development of Celacade(TM), plans to fund our current activities,
statements concerning our partnering activities and health regulatory
submissions, strategy, future operations, future financial position, future
revenues, projected costs, prospects, plans and objectives of management. In
some cases, you can identify forward-looking statements by terminology such as
"may", "will", "should", "expects", "plans", "anticipates", "believes",
"estimated", "predicts", "potential", "continue", "intends", "could", or the
negative of such terms or other comparable terminology. We made a number of
assumptions in the preparation of these forward-looking statements, including
assumptions about the nature, size and accessibility of the market for
Celacade in the treatment of chronic heart failure, particularly in Europe,
the regulatory approval process leading to commercialization and the
availability of capital on acceptable terms to pursue the development of
Celacade, and the feasibility of additional trials. You should not place undue
reliance on our forward-looking statements which are subject to a multitude of
risks and uncertainties that could cause actual results, future circumstances
or events to differ materially from those projected in the forward-looking
statements. These risks include, but are not limited to, the outcome of
further ongoing analysis of the ACCLAIM trial results, the requirement or
election to conduct additional clinical trials and the size and design of any
such trails, delays or setbacks in the regulatory approval process,
difficulties in the maintenance of existing regulatory approvals, securing and
maintaining corporate alliances, the need for additional capital and the
effect of capital market conditions and other factors on capital availability,
the potential dilutive effects of any financing, risks associated with the
outcomes of our preclinical and clinical research and development programs,
the adequacy, timing and results of our clinical trials, competition, market
acceptance of our products, the availability of government and insurance
reimbursements for our products, the strength of intellectual property,
reliance on partners, subcontractors, and key personnel, losses due to
fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from
time to time in our public disclosure documents or other filings with the
Canadian and U.S. securities commissions or other securities regulatory
bodies. Additional risks and uncertainties relating to our Company and our
business can be found in the "Risk Factors" section of our Annual Information
Form and Form 20-F for the year ended November 30, 2006, as well as in our
later public filings. The forward-looking statements are made as of the date
hereof, and we disclaim any intention and have no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. Unless otherwise indicated, numerical values indicating
the statistical significance ("p-values") of results included in this document
are based on analyses that do not account for endpoint multiplicity.

    %SEDAR: 00001047E          %CIK: 0001042018

For further information:

For further information: Glenn Neumann, Investor Relations, 2505
Meadowvale Blvd, Mississauga, ON, Canada, L5N 5S2, tel: (905) 817-2004, fax:
(905) 569-9231, www.vasogen.com/investor@vasogen.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890